For the Inventor, By the Inventor

Enter assignee name

Fujirebio Inc.

USPTO Granted Patents = 102

CIPO Patents = 1

EPO Patents = 27

Trademarks = 16

Forward Citations = 721

Loading Chart...

Loading Chart...

165 inventors (with patents filed for the assignee):

Hiroshi Ikawa (22 out of 26 patents)

Tetsuaki Yamaura (13 out of 15 patents)

Yoshihiro Ashihara (12 out of 27 patents)

4. Masakatsu Matsumoto (9 out of 14 patents)

5. Katsumi Aoyagi (8 out of 14 patents)

6. Yoshiaki Uchida (8 out of 9 patents)

7. Masahisa Okada (8 out of 11 patents)

8. Nobuko Watanabe (8 out of 9 patents)

9. Shintaro Yagi (6 out of 10 patents)

10. Masami Sugiyama (6 out of 11 patents)

11. Yoshihiro Kurano (6 out of 6 patents)

12. Yasuko Konagai (6 out of 6 patents)

13. Akiyoshi Kadoiri (6 out of 7 patents)

14. Eiko Mori (6 out of 16 patents)

15. Hisako Kobayashi (6 out of 6 patents)

Core Competencies:

Immunoassay

Cardiac Troponin Assay

Prostaglandin Measurement

PIVKA-II Immunoassay

Monoclonal Antibodies

Nucleic Acid-Bound Polypeptide

Chemiluminescent Assay

Diagnostic Markers

Automated Analyzers

Culture Medium

Modified Nucleobase Measurement

Hepatitis B Virus Detection

102 patents: Sort by Forward Citations

1. 12196768 - Method of testing a blood for macrolide immunosuppressant (2025-01-14),

2. 12038440 - Lectin-binding substance measurement method, lectin-binding substance measurement kit, and capture carrier for use in these (2024-07-16),

3. 11988666 - Lectin-binding substance measurement method, lectin-binding substance measurement kit, and blocked labeled lectin for use in these (2024-05-21),

4. 11802867 - Cardiac troponin assay method and assay reagent (2023-10-31),

5. 11768209 - Method and reagent for measuring thyroglobulin (2023-09-26),

6. 11604199 - Treatment liquid for exclusion of steroid included in cyclodextrin (2023-03-14),

7. 11454632 - Assay method and assay kit for hepatitis B virus S antigen (2022-09-27),

8. 11169162 - Kit and method for measuring prostaglandin E-major urinary metabolite (2021-11-09),

9. 10830771 - PIVKA-II assay method and method for manufacturing reagent or kit for PIVKA-II immunoassay (2020-11-10),

10. 10634676 - Method and kit for simultaneously detecting human parvovirus B19 antigen and antibody (2020-04-28),

11. 10571479 - Vitamin D measurement method and measurement kit (2020-02-25),

12. 10539559 - PIVKA-II measurement method, measurement reagent, and measurement kit (2020-01-21),

13. 10527638 - Automated analyzer and nozzle-cleaning method (2020-01-07),

14. 10138508 - Method for measuring modified nucleobase using guide probe, and kit therefor (2018-11-27),

15. 10107802 - Method for measuring modified nucleobase using solid phase probe, and kit for same (2018-10-23),

Fujirebio Inc. is a global provider of high-quality in vitro diagnostics (IVD) testing solutions. With a focus on infectious diseases, cancer biomarkers, and genetic testing, Fujirebio develops and manufactures a wide range of IVD products for clinical laboratories and healthcare professionals. Their advanced technologies and innovative products contribute to improved patient care and outcomes worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

102 Patents

#467 in Tokyo

#1,083 in Japan

#7,426 in the World

Fujirebio Inc.

Forward Citations = 721

165 inventors:

Hiroshi Ikawa (22 out of 26 patents)

Tetsuaki Yamaura (13 out of 15 patents)

Yoshihiro Ashihara (12 out of 27 patents)

4. Masakatsu Matsumoto (9 out of 14 patents)

5. Katsumi Aoyagi (8 out of 14 patents)

Please report any incorrect information to support@idiyas.com

Loading…